Abakkus funds hold 1.15% of Aether Industries after the September quarter: stock up about 118% in a year, is it still worth buying?
Abakkus funds hold about 1.15% of Aether Industries, about 15.3 lakh shares, after the September 2026 quarter. News reports call it a fresh buy in some places and a raised stake in others, and the sources do not agree on which fund holds it. The stock is up about 118% in a year. September-quarter profit rose 26.6% to ₹68 crore. But at roughly 86 to 98 times earnings, is it still worth buying?
Aether Industries (NSE: AETHER) - Share price: about ₹1,616 at the close on 30 October 2026 (check the live price) - Market cap: about ₹21,450 crore - P/E: about 86x to 98x on most data pages (some show up to 122x), because the earnings basis and date differ - 52-week high about ₹1,813; one-year return about 118%; down about 5% over the last month - Mainboard listing (NSE and BSE)
What Abakkus did, and what we do not know
- Who: Abakkus funds. One source names the Abakkus Flexi Cap Fund; another says only "Abakkus". This is a mutual fund holding, not Sunil Singhania personally - What: about 15.3 lakh shares, 1.15% of the company, worth about ₹237.5 crore as reported (15.3 lakh shares at ₹1,616 would be about ₹247 crore, so the report used a different price date) - Fresh or raised: a news headline says Singhania "raises stake"; a Trade Brains report lists it among six fresh stakes. I could not settle which is right - Price and date: no price or date has been published. This is quarter-end shareholding, not a bulk deal
The holding is small, and it does not change who controls the company: promoters hold about 74.9%, foreign investors about 8.5% and domestic institutions about 9.7%, as reported for September 2026.
What Aether does
Aether Industries is a specialty-chemicals company. It makes specialty chemicals and advanced intermediates for pharma, oil and gas, agrochemicals, material science, photography, coatings and renewables. Some of it is made for the open market and some for named clients under contract (CRAMS, contract research and manufacturing, and CEM, custom or exclusive manufacturing). It was incorporated in 2013 and listed on the main board in 2022.
The September 2026 quarter
Measure Q2 FY27 A year earlier Change ------:---:---: Operating revenue ₹347.2 crore ₹280.1 crore +24% EBITDA ₹110.4 crore ₹85.3 crore +29% EBITDA margin 31.8% 30.5% +1.3 points Profit after tax ₹68.0 crore ₹54.0 crore +26.6%
For the first half of FY27, revenue was ₹673.8 crore (up 27%), EBITDA ₹213.2 crore (up 30%) and profit ₹130.7 crore (up 29%).
The mix is changing
Oil and gas is now the biggest end-market at 33.4% of revenue, against 18.8% a year ago. Pharma fell to 26.6% from 36.6%, and agrochemicals to 7.9% from 13.3%.
The company says contract research and manufacturing work is being negotiated with clients in several sectors, but it has not shared values, customers, products or timing. Management expects oil and gas and material science to be the main growth drivers.
- R&D: ₹40.6 crore in the first half, 6.03% of revenue; a new research building is under construction - New site: ground levelling for a catalyst plant is done, and the building is expected by the first quarter of FY28
I did not find numerical guidance, an order book, capex figures, debt figures or cash-flow data in the news summaries I could read (the company's own presentation may have more), so this article cannot say whether profit turns into cash.
How the price compares
Navin Fluorine trades near 49 times (after an 82% jump in quarterly profit) and Neogen Chemicals near 199 times, so Aether sits between them, though the P/Es are from different dates and earnings bases. All three are expensive on past earnings. The market is paying for growth that is not yet proven.
Risks
- Price: at about 98 times earnings, any slowdown can hit the share price - Concentration: oil and gas is a third of sales; I did not find customer-level data, so I cannot say how much depends on one client - Disclosure gaps: no stated guidance, order book or cash-flow data in what I read - Contract work: CEM and CRAMS deals are not disclosed in value, so growth is hard to check
The one thing to remember A fund holding 1.15% shows interest, not a price anyone can copy. No price or date was published for the buying.
I could not read the company's own filings for this article. The figures come from news reports and data pages, so check them before you act.
Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.
Sources
- https://tradebrains.in/indian-markets/top-6-stocks-in-which-sunil-singhania-bought-fresh-stakes-worth-up-to-1345-cr-in-q2-fy27-12761117 - https://www.tradingview.com/news/moodys:0bac857f2e731:0-up-137-in-1-year-ace-investor-sunil-singhania-raises-stake-in-this-specialty-chemicals-stock-should-you-buy-too/ - https://www.sahi.com/news/aether-industries-posts-q2-consolidated-net-profit-of-68-crore-versus-53-9-crore-yoy - https://www.multibagg.ai/market-pulse/articles/aether-oil-gas-revenue-mix-ppt-cmvuo1a0v001f32qhsnchs8d5 - https://www.investywise.com/aether-industries-presentation-on-financial-results-2 - https://www.tickertape.in/stocks/aether-industries-AET